Drugs / Floradapt Intensive GI
Floradapt Intensive GI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04145856 | Sep 2018 → May 2019 | irritable bowel syndrome | Hospital Juarez de Mexico | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06211062 Comparator | Dec 2022 → Feb 2026 overdue | irritable bowel syndrome, myalgic encephalomeyelitis/chronic fatigue syndrome | Nova Southeastern University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Floradapt Intensive GI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06211062 ↗ |
| Known as | I31 | “I31 is a probiotic formula composed of strains Pediococcus acidilactici CECT7483 and Lactobacillus plantarum CECT7484 and CECT7485, previously shown to improve quality of life...” NCT04145856 ↗ |
| Known as | I31 probiotic | “I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)” NCT04145856 ↗ |
| Modality | Other / unclassified | “I31 is a probiotic formula” NCT04145856 ↗ |